{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:43:57Z","timestamp":1786196637651,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.josat.2026.210062","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:10:44Z","timestamp":1782889844000},"page":"210062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["How do services offered within opioid treatment programs vary based on state methadone policies?"],"prefix":"10.1016","volume":"190","author":[{"given":"Zoe","family":"Lindenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Agniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Cantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2026.210062_bb0010","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.josat.2026.210062_bb0015","series-title":"42 CFR Part 8\u2014Medications for the Treatment of Opioid Use Disorder","author":"CFR","year":"2024"},{"key":"10.1016\/j.josat.2026.210062_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104141","article-title":"Typology of laws restricting access to methadone treatment in the United States: A latent class analysis","volume":"119","author":"Conway","year":"2023","journal-title":"International Journal of Drug Policy"},{"issue":"9","key":"10.1016\/j.josat.2026.210062_bb0025","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1377\/hlthaff.2025.00341","article-title":"Restrictive state opioid treatment program regulations constrain local access to methadone maintenance treatment","volume":"44","author":"Donahoe","year":"2025","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2026.210062_bb0030","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: Population estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.josat.2026.210062_bb0035","author":"Garnett"},{"key":"10.1016\/j.josat.2026.210062_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108008","article-title":"Characterizing variability in state-level regulations governing opioid treatment programs","volume":"115","author":"Jackson","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"7","key":"10.1016\/j.josat.2026.210062_bb0050","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: A systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2026.210062_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107616","article-title":"Characteristics and current clinical practices of opioid treatment programs in the United States","volume":"205","author":"Jones","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.210062_bb0060","series-title":"Status of state medicaid expansion decisions: Interactive map","author":"Kaiser Family Foundation","year":"2023"},{"issue":"4","key":"10.1016\/j.josat.2026.210062_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/haschl\/qxag074","article-title":"Illicit drug supply, naloxone availability, and overdose mortality in the fentanyl era: A systematic review","volume":"4","author":"Khezri","year":"2026","journal-title":"Health Affairs Scholar"},{"issue":"6","key":"10.1016\/j.josat.2026.210062_bb0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17616","article-title":"Availability of medications for opioid use disorder in opioid treatment programs","volume":"8","author":"Lindenfeld","year":"2025","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.210062_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2024.117529","article-title":"Beyond social determinants: Fiscal determinants of overdose death in U.S counties, 2017\u20132020","volume":"364","author":"Lindenfeld","year":"2025","journal-title":"Social Science & Medicine"},{"issue":"5","key":"10.1016\/j.josat.2026.210062_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304256","article-title":"Examining the relationship between social determinants of health, measures of structural racism and county-level overdose deaths from 2017\u20132020","volume":"19","author":"Lindenfeld","year":"2024","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.josat.2026.210062_bb0085","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1176\/appi.ps.202000183","article-title":"Integrating mental health and addiction treatment into general medical care: The role of policy","volume":"71","author":"McGinty","year":"2020","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.josat.2026.210062_bb0090","author":"Medicare Program"},{"key":"10.1016\/j.josat.2026.210062_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108764","article-title":"Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort","volume":"225","author":"Morgan","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.210062_bb3000","series-title":"National Vital Statistics System. Estimates for 2025 and 2026 are based on provisional data","author":"NCHS","year":"2026"},{"key":"10.1016\/j.josat.2026.210062_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","article-title":"Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin","volume":"189","author":"Neale","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.josat.2026.210062_bb0105","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/jama.2024.11913","article-title":"Treatment approaches for opioid use disorder offered in US substance use treatment facilities","volume":"332","author":"Park","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2026.210062_bb0110","author":"Public Law 119\u201321\u2014July 4, 2025"},{"key":"10.1016\/j.josat.2026.210062_bb0115","series-title":"Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH series H-59)","author":"SAMHSA","year":"2024"},{"issue":"5","key":"10.1016\/j.josat.2026.210062_bb0120","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact Of long-term buprenorphine treatment on adverse health care outcomes in Medicaid","volume":"39","author":"Samples","year":"2020","journal-title":"Health Affairs"},{"issue":"9","key":"10.1016\/j.josat.2026.210062_bb0125","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2026.210062_bb0130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsat.2020.01.009","article-title":"Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders","volume":"111","author":"Saunders","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2026.210062_bb0135","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.josat.2026.210062_bb0140","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.josat.2026.210062_bb0145","series-title":"Medications for opioid use disorder save lives","author":"The National Academies Press","year":"2019"},{"key":"10.1016\/j.josat.2026.210062_bb0150","author":"The National Council"},{"key":"10.1016\/j.josat.2026.210062_bb0155","author":"U.S. Department of Agriculture"},{"issue":"2","key":"10.1016\/j.josat.2026.210062_bb0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:28:53Z","timestamp":1786195733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875926001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"alternative-id":["S2949875926001827"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2026.210062","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How do services offered within opioid treatment programs vary based on state methadone policies?","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2026.210062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"210062"}}